Compare HIPO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | OCS |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.5M | 732.4M |
| IPO Year | 2020 | 2022 |
| Metric | HIPO | OCS |
|---|---|---|
| Price | $36.90 | $7.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $40.88 | $36.73 |
| AVG Volume (30 Days) | 161.2K | ★ 291.2K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 235.37 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $468,600,000.00 | N/A |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $34.47 | $365.20 |
| P/E Ratio | $54.66 | ★ N/A |
| Revenue Growth | ★ 25.93 | N/A |
| 52 Week Low | $24.08 | $7.11 |
| 52 Week High | $38.73 | $34.48 |
| Indicator | HIPO | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 72.52 | 24.99 |
| Support Level | $24.68 | N/A |
| Resistance Level | N/A | $13.49 |
| Average True Range (ATR) | 0.88 | 0.44 |
| MACD | 0.37 | -0.04 |
| Stochastic Oscillator | 93.51 | 10.97 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.